Showing results (281-290 of 824) with videos related to
Sort By:
Pageof 83
British Journal of Haematology|February 21, 2006
FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myelomaShaji Kumar, Noopur Raje, Teru Hideshima, et al.Annual Review of Medicine|January 18, 2006
Bortezomib: proteasome inhibition as an effective anticancer therapyPaul G Richardson, Constantine Mitsiades, Teru Hideshima, et al.Current Pharmaceutical Biotechnology|November 2, 2006
Recent advances in the treatment of Multiple MyelomaHiroshi Yasui, Teru Hideshima, Paul G Richardson, et al.Cancer Cell|September 15, 2012
A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistanceDharminder Chauhan, Ze Tian, Benjamin Nicholson, et al.Proceedings of the National Academy of Sciences of the United States of America|March 3, 2010
Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone diseaseSonia Vallet, Siddhartha Mukherjee, Nileshwari Vaghela, et al.Blood Advances|April 23, 2024
Clonal hematopoiesis of indeterminate potential in patients with immunoglobulin light-chain AL amyloidosisPaolo Lopedote, Benjamin Evans, Alfredo Marchetti, et al.JACC. Cardiooncology|March 16, 2026
Cardiovascular Adverse Events Associated With Bispecific T-Cell Engager TherapyOsnat Itzhaki Ben Zadok, Shai Shimony, Shannon Miller, et al.Nature Reviews. Clinical Oncology|January 10, 2018
The bone-marrow niche in MDS and MGUS: implications for AML and MMIrene M Ghobrial, Alexandre Detappe, Kenneth C Anderson, et al.Cell Cycle (Georgetown, Tex.)|October 7, 2004
Mcl-1 regulation and its role in multiple myelomaSteven Le Gouill, Klaus Podar, Jean-Luc Harousseau, et al.British Journal of Haematology|May 12, 2018
Investigational agents in immunotherapy: a new horizon for the treatment of multiple myelomaCindy Varga, Jacob P Laubach, Kenneth C Anderson, et al.Pageof 83